SCHEMBL2274838

SCHEMBL2274838

O=C(Nc1cc(Oc2cccc(Cl)c2)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 2/20 0.66
PYGM P11217 3/20 0.65
PYGL P06737 2/20 0.65
MEN1 O00255 3/20 0.60
PKM P14618 3/20 0.60
KMT2A Q03164 3/20 0.60
NPSR1 Q6W5P4 1/20 0.60
GRIK1 P39086 2/20 0.57
HPSE Q9Y251 1/20 0.55
ADRB1 P08588 1/20 0.54
ADRB3 P13945 1/20 0.54
TDP1 Q9NUW8 2/20 0.54
MAPT P10636 1/20 0.54
GALK1 P51570 1/20 0.53
CASP6 P55212 1/20 0.53
MCL1 Q07820 1/20 0.53
PLEC Q15149 1/20 0.53
ACLY P53396 1/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270287 0.94 PYGM (0.70) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2273110 0.91 SERPINE1 (0.60) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2272347 0.90 SERPINE1 (0.69) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2271588 0.90 SERPINE1 (0.64) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2269075 0.89 SERPINE1 (0.56) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2290709 0.89 SERPINE1 (0.76) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2272043 0.89 SERPINE1 (0.75) SERPINE1MEN1PKMKMT2ANPSR1
SCHEMBL2271920 0.86 SERPINE1 (0.57) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2275201 0.86 ACLY (0.67) SERPINE1PYGMPYGLMEN1PKM
SCHEMBL2269138 0.86 SERPINE1 (0.57) SERPINE1PYGMPYGLMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 SERPINE1 101/4885PYGM 1299/4885PYGL 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.